Life Science Investing BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma at the Annual Conference of the International Papillomavirus Society
Life Science Investing BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
Life Science Investing BioAtla to Present Clinical Data for Mecbotamab Vedotin in Soft Tissue Sarcoma at SITC 2025
Life Science Investing BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA
